Vivos Therapeutics, Inc.
VVOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.02 | -0.05 | 0.72 |
| FCF Yield | -61.57% | -84.05% | -221.72% | -37.95% |
| EV / EBITDA | -1.59 | -0.93 | -0.33 | -1.30 |
| Quality | ||||
| ROIC | -103.60% | -394.08% | -323.19% | -70.77% |
| Gross Margin | 60.00% | 59.93% | 62.52% | 74.65% |
| Cash Conversion Ratio | 1.14 | 0.88 | 0.82 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.11% | -6.50% | 7.04% | 14.01% |
| Free Cash Flow Growth | -4.00% | 37.84% | -13.13% | -212.57% |
| Safety | ||||
| Net Debt / EBITDA | 0.45 | -0.02 | 0.05 | 1.15 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -1,390.79 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -56.22 | -136.24 | -75.35 | -41.28 |